Two drugs before a stem cell transplant for t-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of two drugs, pralatrexate and chidamide, to shrink lymphoma before a stem cell transplant. The goal is to help patients with relapsed or refractory peripheral T-cell lymphoma get a successful transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with peripheral T-cell lymphoma (a type of lymphoma).
- Your lymphoma has come back after treatment or did not completely respond to prior therapy.
- You have at least one tumor that can be seen on a scan (CT or MRI).
- You are able to care for yourself (performance status 0 or 1).
- You have a stem cell donor and are willing to receive a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
Hear when a new Relapsed Peripheral T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.